Teva Pharmaceutical Industries (TEVA) Releases FY18 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.

Several analysts recently commented on the company. ValuEngine upgraded Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research report on Thursday, January 11th. Vetr cut Teva Pharmaceutical Industries from a strong-buy rating to a buy rating and set a $22.63 target price on the stock. in a research report on Thursday, January 11th. Zacks Investment Research cut Teva Pharmaceutical Industries from a hold rating to a sell rating in a research report on Friday, January 12th. BTIG Research cut Teva Pharmaceutical Industries from a buy rating to a neutral rating and set a $24.00 target price on the stock. in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, Leerink Swann raised their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an underperform rating in a research report on Friday, January 26th. Nine investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of Hold and an average target price of $21.54.

Teva Pharmaceutical Industries (NYSE TEVA) traded down $2.07 on Thursday, hitting $18.78. The stock had a trading volume of 41,935,086 shares, compared to its average volume of 19,960,387. The company has a market cap of $19,040.00, a price-to-earnings ratio of -3.20, a PEG ratio of 1.48 and a beta of 0.59. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.17. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. The company’s revenue was down 15.9% compared to the same quarter last year. During the same period last year, the company posted $1.38 EPS. equities research analysts expect that Teva Pharmaceutical Industries will post 3.73 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries (TEVA) Releases FY18 Earnings Guidance” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://sportsperspectives.com/2018/02/08/teva-pharmaceutical-industries-teva-releases-fy18-earnings-guidance.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply